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CASE REPORT
Zoledronic acid-induced hepatotoxicity 
relieved after subsequent infusions in a 
Chinese woman with glucocorticoid-induced 
osteoporosis
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Abstract 
Background: Zoledronic acid (ZOL) is widely used for treatment of glucocorticoid‑induced osteoporosis. The most 
common adverse effects of ZOL treatment are post‑dose symptoms. ZOL‑induced hepatotoxicity has very rarely been 
reported.
Case report: Here, we described a 50‑year‑old Chinese woman who had vertebral fractures and severe back pain 
after glucocorticoid therapy for Behcet disease for 13 years. Three days after ZOL 5 mg infusion in April 2012, serum 
alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma‑glutamyltransferase (GGT) levels 
increased by 7.7, 4.9 and 3.0 times, respectively, compared with pre‑treatment values. Liver protective agents were 
administered per os. Her hepatic enzyme levels returned to nearly normal range 9 days post‑infusion. In the subse‑
quent ZOL infusion with 1 year interval, serum ALT, AST and GGT levels increased slightly after the second infusion 
and were sustained to be normal after the third infusion. Her post‑dose symptoms alleviated in the meantime.
Conclusions: Hepatotoxicity due to ZOL therapy is a rare, but possible adverse effect which may be relieved after 
subsequent infusions.
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Background
Although glucocorticoids may effectively be used in the 
management of inflammatory and immune-mediated 
disorders, persistent use is associated with side effects, 
such as bone loss and increased fracture risk [1]. Zole-
dronic acid (ZOL), a bisphosphonate (BP), intravenous 
5 mg once per year, has been approved for treatment of 
glucocorticoid-induced osteoporosis (GIO) [2, 3]. The 
overall safety of BP treatment is well established. The 
most common adverse effects of ZOL treatment are post-
dose symptoms [4, 5]. BP-induced liver injury is rare. 
Only a few cases [6–15] have been reported including 
two cases of ZOL [13, 14]. We report here in detail the 
case of hepatotoxicity after ZOL treatment, which was 
relieved after subsequent infusions.
Case presentation
The diagnosis of glucocorticoid-induced osteoporosis 
(GIO) was established in a 50-year-old postmenopausal 
Chinese woman in April 2012 when she first presented to 
our clinic. She presented with canker sores, fever, abdom-
inal pain, bloody diarrhea and a past medical history of 
Behcet disease diagnosed in 1999. From then on, she was 
treated with glucocorticoid, which alleviated her symp-
toms. In 2010, she began to have mild back pain. She had 
T7 and L1 vertebral fractures and severe back pain after 
a fall in February 2012 while taking methylprednisolone 
6  mg once per every other day and tripterygium gluco-
side 20 mg twice per day. She was given calcitrol 0.25 μg 
and element calcium 600 mg per day, but her back pain 
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did not improve. She also had diabetes for 3  years and 
received metformin therapy with a plasma HbA1c 6.6 %. 
She reported no recent viral or bacterial infections. She 
did not drink or smoke.
The patient’s physical examination was within normal 
limits, with her weight being 59.5 kg and height 153.5 cm 
(BMI 25.3  kg/m2), except for tenderness in the back. 
Laboratory examinations showed normal liver and renal 
functions. Her T score of lumbar spine and femoral neck 
was −2.8 and −1.6, respectively.
The patient was given zoledronic acid (ZOL) 5  mg 
treatment on April 12, 2012. At the day of infusion, she 
experienced a fever of 38.7  °C, myalgia and arthralgia. 
Acetaminophen 650  mg per os was given once. These 
symptoms were self-limited, resolving in 3 days without 
other nonsteroidal anti-inflammatory drugs (NSAIDs) 
use. Three days after ZOL infusion, serum alanine ami-
notransferase (ALT), aspartate aminotransferase (AST) 
and gamma-glutamyltransferase (GGT) levels increased 
by 7.7, 4.9 and 3.0 times, respectively, compared with 
pretreatment values. Serologic tests for hepatitis A, B, C 
and human immunodeficiency virus were negative. Auto-
immunity markers were also normal. Urea, creatinine 
and blood routine remained normal during follow-up. 
Abdominal ultrasonography revealed fatty liver. Hepato-
protective agents, glucurolactone (100  mg 3/day) and 
polyene phosphatidylcholine capsules (456  mg 3/day), 
were administered per os. Nine days post-infusion, the 
hepatic enzyme levels returned to nearly normal range. 
In the subsequent second and third ZOL infusion with 
1  year interval, the patient co-received glucurolactone 
(100  mg 3/day) per os. Her ALT, AST and GGT levels 
increased slightly after the second infusion and was sus-
tained to be normal after the third infusion (Table 1). Her 
post-dose symptoms alleviated in the meantime with-
out NSAIDs use. The patient obtained significant relief 
from back pain 6 months after the first infusion and had 
no new fractures during the 2 years. Her T score of lum-
bar spine and femoral neck increased to −2.6 and −1.3, 
respectively, in June 2014.
Discussion
We reported a 50-year-old Chinese GIO woman who had 
liver injury after ZOL infusion. Only two cases of hepa-
totoxicity following ZOL infusion have been previously 
reported until now. A 53-year Caucasian postmenopau-
sal woman treated for Paget’s disease [13] and a 73-year 
Chinese woman treated for primary osteoporosis [14] 
reported transient liver injury 1 day and 3 days after ZOL 
infusion. They both remained asymptomatic without 
NSAIDs use. Their serum ALT, AST and GGT returned 
to normal in 7–12 days. After the first ZOL infusion, our 
patient took acetaminophen 650  mg once to mitigate 
pyrexia, myalgia and arthralgia. NSAID (e.g., ibuprofen 
and acetaminophen) administration, even co-prescribed 
with intravenous infusion of bisphosphonates, was recom-
mended for reducing common post-dose symptoms [4, 5]. 
Although NSAID use is a potential cause of liver injury 
[16], the patient took acetaminophen in case of fever in the 
past without hepatotoxicity. In addition, one-time routine 
dose of acetaminophen could not explain the liver injury, 
which indicated that it was an adverse effect of ZOL.
The other eight cases of hepatotoxicity have been 
previously documented with BP treatment including 
Table 1 Treatment history and the changes of liver biochemical markers














2012‑4‑12 ZOL infusion (5 mg) 33 15 45 9.8 2.6 77 Fever 38.7 °C, myalgia, 
arthralgia
2012‑4‑15 glucurolactone (100 mg 
3/d), polyene )
254 73 135 6.3 2.4 –
2014‑4‑18 phosphatidylcholine 
(456 mg 3/d
126 43 112 7.7 2.5 118
2012‑4‑21 66 40 ‑ 11.2 4.3 –
2013‑5‑7 ZOL infusion (5 mg), glu‑
curolactone (100 mg 
3/d)
28 18 30 9.6 2.9 44 Fever 38.0 °C, arthralgia
2013‑5‑10 70 40 46 4.6 1.6 ‑
2013‑5‑13 48 22 43 6.0 2.1 58
2014‑6‑22 ZOL infusion (5 mg), glu‑
curolactone (100 mg 
3/d)
24 20 27 7.2 2.4 51 No fever or pain
2014‑6‑25 31 28 33 5.9 1.6 55
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alendronate [6–10], clodronate [11], risedronate [12] and 
ibandronate [15]. Within all of the previous ten cases, 
six of them had concomitant liver or systemic diseases 
[8–10, 12, 13, 15]. Our patient also had systemic disease 
and nonalcoholic fatty liver disease (NAFLD). Most of 
the adverse hepatic effects were mild to moderate, except 
in one patient with severe cholestatic hepatitis after iban-
dronate infusion. However, this patient had systemic 
lupus erythematosus and was taking hydroxychloroquine 
and atorvastatin at the same time [15]. None of these 
cases reported the following therapy for osteoporosis. To 
our knowledge, this is the first case that revealed ZOL-
induced hepatotoxicity could be relieved after subsequent 
infusions. It is suggested that ZOL could be cautiously 
used again in patients with mild to moderate transient 
elevation of liver enzymes after the first infusion.
The mechanism by which ZOL may cause liver dam-
age is elusive. It has been reported that the number of 
patients who had any of the commonly reported post-
dose symptoms such as pyrexia, myalgia and arthralgia 
was high after the first infusion of ZOL treatment, but 
decreased substantially after subsequent infusions [4]. 
Post-dose symptoms, especially fever after ZOL adminis-
tration, are due to increase in serum TNF-alpha and IL-6 
[17]. TNF-alpha together with other cytokines mediate 
and contribute to liver damages [18]. We speculated that 
cytokines may play a role in the hepatotoxicity of ZOL.
Conclusions
Hepatotoxicity due to zoledronic acid therapy is a rare, 
but possible adverse effect which may be relieved after 
subsequent infusions. We should pay attention to 
patients with concomitant liver or systemic diseases and 
monitor the liver biochemical indicators after treatment.
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